CurveBeam AI describes itself as combining point-of-care diagnostic cone beam CT imaging with artificial intelligence and deep learning expertise across orthopedics and bone health. The company states it was formed in 2022 through a merger of CurveBeam, LLC and StraxCorp Pty Ltd, and that CurveBeam was founded in 2009. Its public product pages name HiRise and InReach as orthopedic imaging systems, while the FDA record ties the applicant name to a separate device, BoneVue. [3][5][7]
The BoneVue clearance and what the filing covers
FDA records list K254072 for BoneVue under applicant Curvebeam AI / Curvebeam, LLC, received December 18, 2025, with a decision date of September 11, 2026. The decision code is SESE, described as substantially equivalent, under a traditional clearance type with a summary statement. The product code is KGI, mapped in the openFDA fields to the device name Densitometer, Bone, device class 2, regulation number 892.1170, and the radiology medical specialty. [1]
The filing address on the record is in Hatfield, Pennsylvania. That address is a filing detail, not a verified headquarters. The record does not describe the device's components, imaging method, indications or performance, and no clinical or diagnostic claims about BoneVue are supported here. [1]
Documented imaging products
CurveBeam AI's own product pages describe HiRise as bilateral, weight bearing CT imaging of the entire lower extremities including hips and pelvis, and of distal upper extremities. InReach is described as point-of-care extremity CT. The company's home page frames its portfolio around weight bearing CT systems intended to support diagnostics, treatment planning and surgical workflows for orthopedic specialists, with listed applications in foot and ankle, knee, hip, distal upper extremity and surgical planning. [3][4]
The same publisher states that weight bearing CT shows 3D anatomy and alignment under physiologic load, information it says conventional supine CT cannot provide. Product pages also describe cone beam CT installation characteristics, including a small footprint, standard power and minimal shielding, and operation by an RT(R) in almost the entire United States. These are company statements about its systems, not independently verified performance results. [3][4]
Corporate identity and lineage
CurveBeam AI's about pages state that CurveBeam AI, Ltd. was formed in 2022 when CurveBeam, LLC and StraxCorp Pty Ltd entered a definitive merger agreement. The same pages place global operations headquarters for product development, regulatory, manufacturing, operations, sales, marketing and customer care in Hatfield, Pennsylvania, with a corporate office in Melbourne, Victoria, Australia. A separate company page states CurveBeam was founded in 2009 and opened a Europe headquarters in London in 2013. [5][6][7]
The FDA applicant string combines Curvebeam AI and Curvebeam, LLC, which matches the merger description at the entity level. The sources do not establish which entity holds the clearance as owner versus brand, and no parent-subsidiary relationship beyond the stated merger is documented. [1][5]
Portfolio snapshot and limits
The supplied collection contains one linked 510(k) record, and its decision count shows one SESE decision. The smaller record sample likewise contains one entry, K254072, with one SESE decision. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1]
No recall records appear in the public information, and no other pathways are represented. Absence of additional filings in this collection does not establish that none exist. Product availability, customers, payor coverage and clinical outcomes are not documented in the numbered sources and remain unknown. [1][3]

